Diabetes

Your daily dose of the clinical news you may have missed.

The investigational weight loss drug showed substantial weight loss among people with obesity or overweight with or without T2D without plateaus.

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.

A quick review of the scope of diabetes in the US and of the gaps in equitable access to care supports the annual call to action from the International Diabetes Federation.

Your daily dose of the clinical news you may have missed.

Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

Your daily dose of the clinical news you may have missed.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Your daily dose of the clinical news you may have missed.

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.

The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Type 2 diabetes and prediabetes were associated with accelerated brain aging, particularly among men and persons with poor cardiometabolic health, according to new research.

The Omnipod 5 is now the first automated insulin delivery system available for both T1D and T2D in the US.

Results of a global analysis of over 30 million cases showed significantly higher odds for suicidal ideation among adults who received semaglutide vs other medications.

Your daily dose of the clinical news you may have missed.

Experts on diabetes provide insights gleaned from the SIMPLE study and outline patient factors that inform treatment decisions.